386
Participants
Start Date
April 22, 2022
Primary Completion Date
September 30, 2025
Study Completion Date
September 30, 2025
Dolutegravir (DTG) and lamivudine (3TC)
Children randomised to the DTG/3TC arm will receive once daily DTG/3TC fixed dose combination dispersible or film-coated tablets dosed using WHO weight bands criteria
SOC
2 nucleos(t)ide reverse transcriptase inhibitor (NRTI) and a third (anchor) drug (either an integrase strand transfer inhibitor (INSTI), a protease inhibitor (PI) or a non- nucleoside reverse transcriptase inhibitor (NNRTI)
King Edward VIII Hospital, Durban
PHRU Klerksdorp, Klerksdorp
PHRU, Soweto
Hospital Universitario 12 de Octubre, Madrid
Prapokklao Hospital, Chanthaburi
Nakornping Hospital, Chiang Mai
Chiangrai Prachanukroh Hospital, Chiang Rai
Khon Kaen Hospital, Khon Kaen
Baylor, Kampala
Joint Clinical Research Centre, Kampala
MUJHU, Kampala
Birmingham Heartlands Hospital, Birmingham
Great Ormand Street Hospital, London
St. Mary's Hospital, London
MRC CTU at UCL
UNKNOWN
AMS-CMU/IRD (PHPT)
UNKNOWN
Chris Hani Baragwanath Academic Hospital
OTHER
Durban International Clinical Research Site
UNKNOWN
Hospital Universitario 12 de Octubre
OTHER
Prapokklao Hospital, Chantaburi
UNKNOWN
Chiangrai Prachanukroh Hospital
OTHER
Nakornping Hospital
OTHER
Khon Kaen Hospital
OTHER_GOV
Kalasin Hospital
OTHER
Joint Clinical Research Center
OTHER
MU-JHU CARE
OTHER
Baylor College of Medicine
OTHER
Great Ormond Street Hospital for Children NHS Foundation Trust
OTHER
University Hospital Birmingham NHS Foundation Trust
OTHER
Department of Clinical Pharmacy, University Medical Centre St Radboud, The Netherlands.
OTHER
Advanced Pathogens Diagnostics Unit, University College London Hospitals
UNKNOWN
Centre for Health Economics, University of York
UNKNOWN
Department of Molecular and Clinical Pharmacology, University of Liverpool
UNKNOWN
St Mary's NHS Trust
OTHER_GOV
Chang Mai Univerity
UNKNOWN
PENTA Foundation
NETWORK